Transcriptional regulatory networks in human lung adenocarcinoma

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 961-966

  Meng, Xiangrui ^a   Lu, Peng ^b   Bai, Hua ^b   Xiao, Peng ^b   Fan, Qingxia ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b People's Hospital of Zhengzhou   (China)

Author keywords

Adenocarcinoma; Network motif analysis; Regulatory network

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIN D3; GELATINASE B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CCAAT ENHANCER BINDING PROTEIN BETA GENE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ETS VARIANT 4 GENE; FEMALE; FRIEND LEUKEMIA VIRUS INTEGRATION 1 GENE; GENE; GENE REGULATORY NETWORK; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MICROARRAY ANALYSIS; NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B- CELLS 1 GENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL ACUTE LYMPHOCYTIC LEUKEMIA 1 GENE; TRANSCRIPTION REGULATION; UPREGULATION;

ADENOCARCINOMA; ADENOVIRUS E1A PROTEINS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CYCLIN D3; DOWN-REGULATION; GENE REGULATORY NETWORKS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPROTEIN LIPASE; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; NF-KAPPA B P50 SUBUNIT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

FRIEND MURINE LEUKEMIA VIRUS;

EID: 84866460325     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1034     Document Type: Article

References (52)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Travis WD, Travis LB and Devesa SS: Lung cancer. Cancer 75 (Suppl 1): 191-202, 1995.
3. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.
4. Marks JL, Broderick S, Zhou Q, et al: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3: 111-116, 2008. (Pubitemid 351323183)
5. Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4: 22-29, 2009.
6. Gill RK, Yang SH, Meerzaman D, et al: Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30: 3784-3791, 2011.
7. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075, 2008.
8. Gao SP, Mark KG, Leslie K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007. (Pubitemid 350224094)
9. Hiramatsu M, Ninomiya H, Inamura K, et al: Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer 70: 94-102, 2010.
10. Stearman RS, Dwyer-Nield L, Zerbe L, et al: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167: 1763-1775, 2005. (Pubitemid 41713326)
11. Wachi S, Yoneda K and Wu R: Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21: 4205-4208, 2005. (Pubitemid 41724298)
12. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3, 2004.
13. Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
14. Wingender E: The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform 9: 326-332, 2008.
15. Jiang C, Xuan Z, Zhao F and Zhang MQ: TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res 35: D137-D140, 2007. (Pubitemid 46056185)
16. Kanehisa M: The KEGG database (Review). Novartis Found Symp 247: 91-101, 2002.
17. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
18. Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 60: 1129-1138, 2000.
19. Theocharis S, Kanelli H, Politi E, et al: Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36: 249-255, 2002. (Pubitemid 34497122)
20. Keshamouni VG, Reddy RC, Arenberg DA, et al: Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108, 2004. (Pubitemid 38142244)
21. Hall PA, Kearsey JM, Coates PJ, Norman DG, Warbrick E and Cox LS: Characterisation of the interaction between PCNA and Gadd45. Oncogene 10: 2427-2433, 1995.
22. Zhan Q, Antinore MJ, Wang XW, et al: Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18: 2892-2900, 1999. (Pubitemid 29250879)
23. Bruemmer D, Yin F, Liu J, et al: Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells. Circ Res 93: e38-e47, 2003.
24. Na YK, Lee SM, Hong HS, Kim JB, Park JY and Kim DS: Hypermethylation of growth arrest DNA-damage-inducible gene 45 in non-small cell lung cancer and its relationship with clinicopathologic features. Mol Cells 30: 89-92, 2010.
25. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15: 5336-5348, 1996. (Pubitemid 26336216)
26. Li L, Beauchamp MC and Renier G: Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 165: 101-110, 2002. (Pubitemid 35223171)
27. Kuemmerle NB, Rysman E, Lombardo PS, et al: Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther 10: 427-436, 2011.
28. Cerne D, Zitnik IP and Sok M: Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. Arch Med Res 41: 405-409, 2010.
29. Shindoh M, Higashino F and Kohgo T: E1AF, an ets-oncogene family transcription factor (Review). Cancer Lett 216: 1-8, 2004. (Pubitemid 39410490)
30. Hiroumi H, Dosaka-Akita H, Yoshida K, et al: Expression of E1AF/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: Its relevance in cell motility and invasion. Int J Cancer 93: 786-791, 2001. (Pubitemid 32761692)
31. Higashino F, Yoshida K, Noumi T, Seiki M and Fujinaga K: Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 10: 1461-1463, 1995.
32. Keld R, Guo B, Downey P, Gulmann C, Ang YS and Sharrocks AD: The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer 9: 313, 2010.
33. Truong A and Ben-David Y: The role of Fli-1 in normal cell function and malignant transformation (Review). Oncogene 19: 6482-6489, 2000. (Pubitemid 32108438)
34. May WA, Arvand A, Thompson AD, Braun BS, Wright M and Denny CT: EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 17: 495-497, 1997. (Pubitemid 27518406)
35. Thompson AD, Teitell MA, Arvand A and Denny CT: Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 18: 5506-5513, 1999. (Pubitemid 29481497)
36. Im YH, Kim HT, Lee C, et al: EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor β type II receptor gene. Cancer Res 60: 1536-1540, 2000. (Pubitemid 30183421)
37. Hahm KB, Cho K, Lee C, et al: Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23: 222-227, 1999. (Pubitemid 29455398)
38. Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V and Dei Tos AP: Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol 17: 547-552, 2004. (Pubitemid 38868421)
39. Pereira R, Quang CT, Lesault I, Dolznig H, Beug H and Ghysdael J: FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts. Oncogene 18: 1597-1608, 1999. (Pubitemid 29108060)
40. Grumont RJ, Fecondo J and Gerondakis S: Alternate RNA splicing of murine nfkb1 generates a nuclear isoform of the p50 precursor NF-kappa B1 that can function as a transactivator of NF-kappa B-regulated transcription. Mol Cell Biol 14: 8460-8470, 1994.
41. Wharry CE, Haines KM, Carroll RG and May MJ: Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol Ther 8: 1567-1576, 2009.
42. Hiscott J, Marois J, Garoufalis J, et al: Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231-6240, 1993. (Pubitemid 23292617)
43. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F and Haugen A: Polymorphisms of the interleukin-1 β gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 109: 353-356, 2004. (Pubitemid 38252762)
44. Hu HM, Tian Q, Baer M, et al: The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. J Biol Chem 275: 16373-16381, 2000. (Pubitemid 30366955)
45. Yamaji H, Iizasa T, Koh E, et al: Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53: 786-792, 2004. (Pubitemid 39149905)
46. Xiao W, Hodge DR, Wang L, Yang X, Zhang X and Farrar WL: Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 61: 354-370, 2004. (Pubitemid 39564278)
47. Tang T, Shi Y, Opalenik SR, et al: Expression of the TAL1/SCL transcription factor in physiological and pathological vascular processes. J Pathol 210: 121-129, 2006. (Pubitemid 44288188)
48. Erez A, Perelman M, Hewitt SM, et al: Sil overexpression in lung cancer characterizes tumors with increased mitotic activity. Oncogene 23: 5371-5377, 2004. (Pubitemid 39005812)
49. Glubb DM, Cerri E, Giese A, et al: Novel functional germline variants in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17: 5257-5267, 2011.
50. Sanmartin E, Jantus Lewintre E, Sirera R, et al: Soluble vascular endothelial growth factor receptor 2 (VEGFR2): New biomarker in advanced non-small cell lung cancer (NSCLC)? J Clin Oncol (Suppl) 27: e22108, 2009.
51. Tanaka A, Itoh F, Nishiyama K, et al: Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis. Blood 115: 4138-4147, 2010.
52. Tanaka A, Itoh F, Itoh S and Kato M: TAL1/SCL relieves the E2-2-mediated repression of VEGFR2 promoter activity. J Biochem 145: 129-135, 2009.